Cargando…

Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review

BACKGROUND: There is a concern that influenza vaccination may increase the incidence of immune‐related adverse events in patients receiving immune checkpoint inhibitors (ICIs). The aim of this systematic review was to summarize the available data on the safety and efficacy of influenza vaccination i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spagnolo, Francesco, Boutros, Andrea, Croce, Elena, Cecchi, Federica, Arecco, Luca, Tanda, Enrica, Pronzato, Paolo, Lambertini, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365730/ https://www.ncbi.nlm.nih.gov/pubmed/34021591 http://dx.doi.org/10.1111/eci.13604

Ejemplares similares

Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma
por: Boutros, Andrea, et al.
Publicado: (2021)

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?
por: Tanda, Enrica Teresa, et al.
Publicado: (2021)

Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient
por: Boutros, Andrea, et al.
Publicado: (2020)

Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature
por: Boutros, A., et al.
Publicado: (2023)

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
por: Awadalla, Magid, et al.
Publicado: (2019)

How to Protect Ovarian Function before and during Chemotherapy?
por: Arecco, Luca, et al.
Publicado: (2021)

Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint Inhibitors
por: Groeneveld, Geert H, et al.
Publicado: (2020)

Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors?
por: Tanda, Enrica Teresa, et al.
Publicado: (2021)

Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis
por: Lopez-Olivo, Maria A., et al.
Publicado: (2022)

Current State of Target Treatment in BRAF Mutated Melanoma
por: Tanda, Enrica Teresa, et al.
Publicado: (2020)

How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma
por: Marseglia, Mariarosaria, et al.
Publicado: (2021)

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
por: Genova, Carlo, et al.
Publicado: (2022)

Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis
por: Righini, Matteo, et al.
Publicado: (2022)

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
por: Vanni, Irene, et al.
Publicado: (2020)

Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase
por: Gatti, Milo, et al.
Publicado: (2021)

Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
por: Cantini, Luca, et al.
Publicado: (2023)

Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
por: Garutti, M., et al.
Publicado: (2021)

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
por: Mandala, Mario, et al.
Publicado: (2021)

Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors
por: Gilbert, Danielle, et al.
Publicado: (2023)

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma
por: Amaro, Adriana Agnese, et al.
Publicado: (2023)

Gender-specific aspects related to type of fertility preservation strategies and access to fertility care
por: Perachino, Marta, et al.
Publicado: (2020)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
por: Zhang, Liyan, et al.
Publicado: (2021)

Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors
por: Moshirfar, Majid, et al.
Publicado: (2022)

Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors
por: Valachis, Antonios, et al.
Publicado: (2021)

Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer
por: Parisi, Francesca, et al.
Publicado: (2020)

COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis
por: Ruiz, Juan Ignacio, et al.
Publicado: (2023)

The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
por: Vanni, Irene, et al.
Publicado: (2020)

Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis
por: Reggiani, Francesco, et al.
Publicado: (2023)

QUALITY OF LIFE IN OLDER ADULTS RECEIVING IMMUNE CHECKPOINT INHIBITOR THERAPY
por: Hoogland, Aasha I, et al.
Publicado: (2019)

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors
por: Panneerselvam, Kavea, et al.
Publicado: (2022)

Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors
por: Vasavada, Shaleen, et al.
Publicado: (2022)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022)

Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis
por: Pantano, Francesco, et al.
Publicado: (2022)

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e9e4k4ahtbog3alnujp5bbe4bc